Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Pluri Inc

PLUR ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: N/A

Last Close

$1.05

▲ +3.96%

Market Cap $12.22M · Vol 1.89K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$12.22M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

40.81

Momentum

Beta

0.68

vs Market

52W High

$4.85

78.35% below

52W Low

$0.90

16.67% above

Volume

1.89K

Avg 6.46K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

57.48%

Public shares

Shariah Compliance8 STANDARDS

✗ Pluri Inc (PLUR) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does PLUR pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+9.36%

-23.91%

-53.13%

-69.12%

YTD

-64.88%

-74.58%

-76.09%

-94.77%

Financials & Valuation

TTM · Annual

Total Revenue	$1.02M
Net Income	$-25,369,000.00
Revenue Growth (YoY)	-15.83%
Gross Margin	44.59%
Operating Margin	-2,454.53%
Net Profit Margin	-2,496.95%
ROE	N/A
ROA · ROIC	-79.90% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	20.04
P/B	N/A
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	12.34M

Technical Indicators

50-Day SMA	$1.39
200-Day SMA	$2.57
RSI (14)	40.81
Beta	0.68
52-Week High	$4.85
52-Week Low	$0.90

Volume Today	1.89K
Avg Daily Volume (30D)	6.46K
Relative Volume	0.29x
Volatility (10D)	74.29
Volatility (30D)	73.15
Free Float	57.48%

Analyst Consensus

N/A

Current Price $1.05

Mean Target N/A

52W Low$0.90 52W High$4.85

Current

Target

$0.90 $4.85

Current Analyst target

· 0 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001S8QJB7

ISINUS72942G2030

CountryIsrael

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +0.24% ONC BeOne Medicines AG +0.31% 068270.KS Celltrion, Inc. -0.11% MEDP Medpace Holdings, Inc. -2.84% ABVX Abivax SA -3.83%

Company Profile

Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.